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C. Garcı´a-Madrid,1* M. Josa,1 V. Riambau,1 C.-A. Mestres,1 J. Muntan˜a2 and J. Mulet11Department of Cardiovascular Surgery, Institut of Cardiovascular Diseases, and 2Angioradiology Unit,
Hospital Clı´nic, University of Barcelona, Barcelona, SpainPurpose. To assess early and intermediate results of endovascular repair of abdominal aortic aneurysms (EVAR), and to
compare them with open surgery (OS) in concurrent patients suitable for both types of treatment.
Methods. During 3 years, 180 patients with AAA underwent repair. We excluded patients with ruptured aneurysms (33),
juxtarenal aneurysms (11), iliac aneurysms (8), with peripheral embolization (2) and those treated with a cryopreserved
homograft (2). From the remaining patients (nZ124), we selected those suitable for both techniques (nZ83), of which 53
were treated by EVAR and 30 by OS. Analysis was performed using Kaplan–Meier curves and Log Rank tests.
Results. Hospital mortality was not significantly higher in the OS group (6.6% OS vs. 3.7% EVAR), pZ0.55. The EVAR
group had significantly shorter operative time, length of hospital stay and less blood loss. The median follow up time was
2.18 years for OR and 1.58 years for EVAR. There were no conversions from EVAR to OS and no differences in late survival
(pZ0.255, Cox regression analysis) with a cumulative survival rate at 3 years of 89% for EVAR and 73% for OS. By 3 years
24% (95% CI, 11–47%) of EVAR patients had presented endoleaks with an endovascular re-intervention rate of 27% (95%
CI, 13–50%). One patient in the OS group needed a late open intervention.
Conclusions. EVAR compares favourably with OS in terms of reduction of operative time, hospital length of stay and blood
loss. This study did not show a difference in early or late mortality. EVAR durability remains the most critical issue to be
addressed.Keywords: Endograft; Endovascular prosthesis; Abdominal aorta; Aortic aneurysm; Mortality.Introduction
Abdominal aortic aneurysm (AAA) is present in 5–9%
of males above 65 years of age.1,2 The incidence of
AAA has increased in the past years and can currently
be estimated in 25–45/100,000/year.3 The natural
history of AAA shows a trend towards progressive
enlargement and rupture.4 AAA represents the 13th
cause of death in the US (0.8% of all deaths).5 A similar
mortality (0.9%) was observed in an European study
(England and Wales).6
Several techniques have been used to treat AAA
over the years. In 1990 Juan-Carlos Parodi in Buenos
Aires, performed successful endovascular abdominal
aneurysm repair.7 Since then many published papers
have tried to focus attention on the early results of
endovascular repair of AAA (EVAR). The current leveling author. C. Garcı´a-Madrid, MD, Section of Vascular
itute of Cardiovascular Diseases, Hospital Clı´nic of
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0365 + 08 $35.00/0 q 2004 Elsevier Ltd. All rights reserof knowledge indicates that EVAR of AAA seems to be
a less invasive therapeutic option. In spite of it there is
limited information available about the real benefit
when compared with the conventional open repair.
The aim of this study is to compare early and
intermediate results of EVAR and OS in consecutive
concurrent patients that were eligible for both tech-
niques, and were treated either with EVAR or OS.Material and MethodsPatients
Between March 1997 and August 2000, 180 patients
with the diagnosis of AAA were treated at our
Institution. The indication for surgery was established
for all those cases in which the transverse diameter of
the AAA was larger than 5 cm. During the study
period 124 elective asymptomatic infra-renal AAAEur J Vasc Endovasc Surg 28, 365–372 (2004)
doi:10.1016/j.ejvs.2004.06.015, available online at http://www.sciencedirect.com onved.
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with OS.
EVAR was performed in those cases with suitable
aortic morphology, advanced age (usuallyO70 years),
significant co-morbidity and high anesthetic risk (ASA
III–IV). These criteria were used to select the cases in
the initial steps of our clinical series. With growing
experience we have been less restrictive with regards
to aneurysmal involvement of the common iliac
arteries, so that we have included a progressively
larger number of cases of type E AAA (EUROSTAR
Classification).8 Pre- or intraprocedural embolization
of one or both (sequential) internal iliac arteries was
done in 30% of cases.
Open surgical repair was indicated in those patients
with the following profile: younger age (usually !70
years), with no high risk factors even though they were
considered suitable for EVAR by anatomical criteria.
These patients were operated under general anesthesia
and the surgical approach included a midline or upper
transverse laparotomy, at the discretion of the attend-
ing surgeon. The aneurysm was excised and the aorta
reconstructed with a straight tube or with a bifurcated
graft.
From an overall population of 180 patients treated
at our Institution for AAA in the study period, we
focused on a population of 124 patients. We excluded
from consideration for EVAR eight patients with iliac
artery aneurysms. We also excluded 33 ruptured
aneurysms, 11 cases of juxtarenal aneurysms, two
symptomatic patients with distal embolization and
two patients treated with a cryopreserved homograft.Study design
Therefore 124 patients electively treated for AAA were
included in the study: 81 were treated with EVAR and
43 with OS. Among them, we selected all patients
where either EVAR or OS was suitable. The following
criteria were used to define this population suitable for
both types of repair:(a)EurFrom the EVAR group we excluded all patients not
suitable for OS considering their high surgical/
anaesthetic risk (28 patients) (Table 1).(b) From the OS group we excluded all patients not
suitable for EVAR because of anatomical criteria
(13 patients) (Table 1).Following this second selection, the final study
population for analysis consisted in all patients that
were considered suitable for both types of repair,
EVAR and OS, this included a total of 83 patients, 53
who had received EVAR and 30 who had received OS.J Vasc Endovasc Surg Vol 28, October 2004Preoperative assessment of co-morbidities was
done taking into account eight risk factors, classified
in four degrees of severity according to the guidelines
of the Society for Vascular Surgery/International
Society for Cardiovascular Surgery, North American
Chapter (SVS/ISCVS).9 The American Society of
Anesthesiologists (ASA) classification10 was also used.
The morphometric study was performed by two
independent reasearchers following the EUROpean
collaborators on Stent-graft Techniques for Abdominal
aortic aneurysm Repair (EUROSTAR) Classification8
and the Reporting standards for infrarenal endo-
vascular abdominal aortic aneurysm repair.11
In addition to routine examinations (blood chem-
istries, chest X-ray and ECG we performed preopera-
tive digital subtraction angiography with a calibrated
catheter, abdominal computed tomography (CT)
with/without 3D reconstruction and/or magnetic
resonance angiography. Data collection were prospec-
tive in the EVAR group as these patients were already
enrolled in the EUROSTAR registry. In the OS group,
data collection was retrospective.
The endovascular stents implanted in the EVAR
group were those available throughout the study
period, Scientific Corp, Oakland, NY (24 bifurcated, 1
straight), Excluderw (W.L. Gore and Associates,
Flagstaff, AZ) (10 bifurcated), Talentw (Medtronic
AVE, Santa Rosa, Calif) (8 bifurcated, 2 aorto-uni-
iliac), Zenithw (Cook, Bloomington, IN) (1 bifurcated, 2
aorto-uni-iliac), Lifepathw (Edwards Lifesciences) (3
bifurcated), AneuRxw (Medtronic AVE, Santa Rosa,
Calif) (1 bifurcated,1 aorto-uni-iliac). In the OS group
25 Dacron (Vascutek, Boston Scientific Corporation,
NY, NY) and 5 PTFE (W.L. Gore and Assoc, Flagstaff,
AZ) prostheses were implanted (18 bifurcated and 12
straight).Follow-up
EVAR patients were followed according to the EURO-
STAR registry protocol. The patients were reviewed in
outpatient clinic and 4-view plain abdominal X-ray
and CT abdominal scans were performed at 1, 3, 6, 12,
18 and 24 months after the procedure and every year
thereafter. In the OS group, the follow up information
was updated by physical examination and abdominal
CT scan within the last 6 months.Statistical analysis
For each of the baseline characteristics (age, sex,
weight) risk factors (16 variables) and early results
(17 variables) a description and comparison by means
Table 1. Causes for rejection to obtain matched patients
Exclusion from OS group [there rejected for EVR by
anatomic criteria (nZ13)]
Exclusions from EVR group [there rejected for OS by
co-morbidity (nZ28)]
Iliac angulation or aneurysm Cardiac disease
Aortic neck!10 mm and thromboO3 mm Severe ischemia 15
Aortic neck!10 and angulationO908 Transplant waiting list 2
Iliac angulationO458. Calcification Implanted desfibrilator 1
Small iliac diameter (6 mm). D4 !20 mm Severe respiratory disease 11
Short aortic neck. Calcium Cirrhosis (transplant) 1
Iliac aneurysms Chronic renal failure
Great aortic neck angulation Hemodialysis 2
Proximal neck short and pyramidal Peritoneal dia´lisis 1
Proximal neck angulated and pyramidal Renal transplant 1
Iliac artery tortuoses and calcified Hostile abdomen hostil, obesity,.
Big iliac aneurysms (50 mm)
Endovascular Repair vs. Open Surgery of AAA 367of non-parametric tests has been performed (c2, c2 for
linear trends and the Wilcoxon Rank Sum test). For
intermediate follow-up events a description of the
number of events, follow-up time for each group and
survival analysis by means of the Kaplan–Meier and
Log Rank test were performed. The Intercooled Stata
6.0 software was used (Stata Corporation, TX, USA).
The temporal characterization of clinical results
include: (1) initial or early results for the outcome
reported within a 30-day or same stay time frame. This
refers to the procedure (endovascular or open surgi-
cal), the first 30 postoperative days or longer period if
the patient required prolonged hospitalization with-
out discharge; and (2) intermediate or mid-term
results refer up to 5 years after endograft implantation,
as suggested by the recommendations of the Reporting
standards for endovascular aneurysm repair.12ResultsTable 2. Demographic and clinic patients characteristics
Variables Endovascular
repair (nZ53)
Open surgery
(nZ30)
P value
Median age (years)
(range)
73 (52–85) 70 (50–90) 0.035a
Sex (M/F) 51/2 28/2 NSb
Mean aneurysm
diameter (mm)
62 64 NSa
Hypertensio´n 45(85%) 18(60%) NSc
Diabetes mellitus 12(24%) 2(7%) NSc
Smoker 46(87%) 18(65%) NSc
Cardiac disease 36(68%) 16(54%) NSc
Carotid disease 6(11%) 2(7%) NSc
cBaseline characteristics
The baseline characteristics indicated a good matching
between individuals of both groups as shown in
Table 2. There were no statistically significant differ-
ences in sex, anesthetic risk, previous laparotomy,
lipid profile, cardiac risk, carotid disease or renal
failure. However, patients in the OS group were
significantly younger [70 (52–85) years vs. 73 (50–90),
pZ0.035] with a lesser degree of associated pulmonary
pathology (pZ0.023), but they had more complex
aortic anatomy (pZ0.046) (Fig. 1).Hyperlipemia 29(55%) 11(37%) NS
Renal disease 13(25%) 7(24%) NSc
Pulmonar disease 42(70%) 15(50%) 0.023c
Previus laparotomy 18(34%) 6(20%) NSb
ASA III 48(91%) 27(90%) NSc
a Wilcoxon Rank Sum test.
b c2 test.
c c2 test for lineal regression.Procedure
There were statistically significant differences among
all procedure variables in favour of the EVAR (Table 3).
Mean procedure time was shorter in the EVAR groupthan in the OS group (125 min vs. 180 min), even
though five patients in the EVAR group were
implanted with an aorto-uni-iliac stent-graft, a pro-
cedure that requires a concomitant femoro-femoral
crossover by-pass graft. Regional anaesthesia was
used in 87% of the patients in the EVAR group. All
the patients in the OS group received general
anaesthesia. Furthermore, patients in the OS group
had a significantly higher transfusion requirement for
packed red cells and plasma. Patients in the OS group
had a longer length of stay in the postoperative
monitoring unit (median 17 h vs. 2 h in the EVAR
group) and in the ward before discharge (median 6
days vs. 2 days). There were no cases of conversion in
the EVAR group.Early results (30 days or in hospital)
Early mortality was higher in the OS group (OS 6.6%,
nZ2/30 vs. EVAR 3.7%, nZ2/53), however, this
difference is not statistically significant when theEur J Vasc Endovasc Surg Vol 28, October 2004
Fig. 1. Anatomic EUROSTAR classification of matched patients. c2 test (pZ0.046).
C. Garcı´a-Madrid et al.368analysis is performed using the c2 test (pZ0.554).
Causes of mortality in the OS group were myocardial
infarction (nZ1) and multi-organ failure (nZ1). In the
EVAR group 2 patients died from myocardial infarc-
tion on the second and fourth day, respectively.
Complications have been defined following the
recommendations of the Reporting Deaths and Com-
plications of the SVS/ISCVS.9 The EVAR group had a
higher incidence of local complications, however, in
the OS group the complications were systemic.
Peri-operative endoleaks were seen in the post-
procedural angiogram in 9.4% of the EVAR cases (5
patients). Two were type I endoleaks (White classifi-
cation13) and resolved during the diagnostic pro-
cedure. One proximal leak was occluded with a
valvuloplasty balloon (Baltw) and the second distal
leak was occluded using an extension stent-graft.
Three patients (5.6%) presented with a type II
endoleak at the end of the procedure (inferior
mesenteric 1, lumbar 2), but these leaks have dis-
appeared has spontaneously during the follow-up.Intermediate-term results
Mortality
Median follow-up time in the OS group was 2.18 and
1.58 years in the EVAR group. During the follow up
there were 11 deaths, six in the OS group (0.092
deaths/year) and five in the EVAR group (0.054
deaths/year). These differences were not statistically
significant (pZ0.245, by Log Rank test), although in
the EVAR group the risk of death was half that of theTable 3. Comparison variables of the procedure
Variables Open s
Operative time (min)(range) 180 (12
General anesthesia 30(100%
Packed red cells/patient 3.1
Median time in intermediate care (hours) (C25;C75) 17 (17–
Median length of stay (days) (C25;C75) 6.0 (5.0
Wilcoxon Rank Sum test.
Eur J Vasc Endovasc Surg Vol 28, October 2004OR group (hazard ratio 0.50, 95% CI 0.15–1.64, pZ
0.255, Cox Regression analysis). When results were
adjusted for baseline differences, the hazard ratio was
0.40 (95% CI 0.05–3.03, pZ0.374 Cox Regression
analysis). At 3 years 27% (95% CI 12–52%) patients
in the OS group and 11% (95% CI 0.04–23%) in the
EVAR group had died. The causes of death were in the
OS group: neoplasm (nZ3) and myocardial infarction
(nZ1), and in the EVAR group: neoplasm (nZ1),
myocardial infarction (nZ1), and respiratory infection
(nZ1). No death was related to the stent-graft or the
procedure (Fig. 2).Late endoleaks
Late endoleaks were detected in seven patients
(13.2%). The type of endoleak, its characteristics and
treatment are described in Table 4. One type III
endoleak (due to a limb disconnection) leading to
rupture of the AAA was solved by means of a
percutaneously implanted stent extension. At 3 years
of cumulated follow-up, 24% of the patients had a late
endoleak (95% CI 11, 47%). Two patients in this group
had a second late endoleak. In the OS group no case of
endoleak (false aneurysm) was detected by CT scans.
However, a new common iliac artery aneurysm was
found in a patient implanted with a bifurcated graft.
This aneurysm is now being closely followed (Fig. 3).Reinterventions
There was only one case of reoperation in the OS
group because of abdominal wound muscle disrup-
tion, whereas in the EVAR group eight patientsurgery (nZ30) Endovascular repair (nZ51) p value
0–300) 125 (50–360) 0.000
) 7(13%) 0.000
0.3 0.000
48) 2 (0.0–2.0) 0.000
–7.0) 2.0 (2.0–2.0) 0.000
Fig. 2. Survival of patients following endovascular or open repair. Kaplan–Meier curves. Log Rank test (pZ0.255).
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migration (pZ0.0553). At 3 years of cumulated
follow-up, 27% of the patients in the EVAR group
required at least one re-intervention (Fig. 4).Discussion
The aim of this study is to compare the early and
intermediate-term clinical results after OS and EVAR
in the treatment of infra-renal AAA. To obtain relevant
and valuable information derived from this study we
had to analyze comparable groups of patients. A key
issue was adequate selection of consecutive patients.
Patients had to be comparable with regards to the
anatomy of the aneurysm (diameter) and baseline
patient characteristics (risk factors) and had to be
suitable to either EVAR or OS. We therefore excluded
from the EVAR group those patients not suitable for
conventional surgery because of their high-risk profile.
From the OS group we excluded those patients
presenting with aneurysms with anatomic andTable 4. Late endoleaks (seven patients) and treatment
Type Onset Cause
Type III 17 months Stent fracture and po
Type III 9 months Stent fracture
Type III 18 months Stent and some sutu
Type III 36 months Limb disconnection
Type III (symptomat) 33 months Limb disconnection
Type II 24 months Inferior mesenteric a
Type I 30 months Proximal limb migra
Type II 27 months Lumbar artery
Type III 30 months AAA angulation andmorphometric criteria not suitable for EVAR. We
therefore had a series of comparable patients who
were treated under similar conditions (surgeons,
anesthetists, drugs, etc.) in both groups.
The study groups were matched for the variables
studied (eight risk factors following the SVS/ISCVS
classification), the exception being mean age (73 years
for EVAR patients vs. 70 years for OS patients) and the
more severe respiratory disease in the EVAR group.
The aneurysm diameter was similar, but anatomic
type following the EUROSTAR classification was more
complex in the OS group as these patients had more
iliac artery involvement.
Peri-operative mortality was lower in the EVAR
group, although the difference did not reach statisti-
cal significance (3.7 vs. 6.6%), pZ0.55. However,
these results did include the learning curve for
EVAR. Peri-procedural mortality associated to EVAR
has been reported to range between 2.5 and 6%,
considering the learning curve, surgical risk and
sample size.14–17 Mortality of OS usually ranges
between 2 and 8%.17–21Treatment
lyester perforation New stent graft (rightObifurcated)
Bifurcated stent graft
res fracture Aorto-uni-iliac stent graft
Iliac extension
Iliac extension
rtery Embolisation
tion Iliac extension
Embolisation
distal endoleak Iliac extension
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Fig. 3. Freedom for endoleaks or graft failure. Kaplan–Meier curves. Log Rank test (pZ0.01).
C. Garcı´a-Madrid et al.370Patients in the OS group were high-risk cases as is
shown by their associated pathology and that only
10% of them were classified as ASA II class. This is
probably due to the patterns of referral in a tertiary-
care University Hospital like our Institution.
The results of the procedure with regards to length
of the operation, length of stay (median 48 h) and
blood loss were highly favourable in the EVAR group.
Reported conversion rates in the literature are 2–4%.15
We had no cases of conversion from EVAR to OS,
probably due to a careful selection of patients.
Morbidity was mostly due to systemic complications                   
                 
                          
 
Fig. 4. Freedom for re-intervention at 3 years. K
Eur J Vasc Endovasc Surg Vol 28, October 2004in the OS group and local complications in the EVAR
group.
Mid-term clinical and technical success according
to the recommendations of the Reporting Standards
for infrarenal endovascular aortic aneurysm repair,11
were in the EVAR group 96.3 and 90.6%, respec-
tively, and 100% for both clinical and technical
success in the OS group. Primary technical success
does not take into account the major complications
in the OS group. If we consider major complications,
the primary technical success at 30 days after the
procedure (absence of death, endoleak and major               
         
aplan–Meier curves. Log rank test (pZ0.055).
Endovascular Repair vs. Open Surgery of AAA 371complications) was 88.7% the EVAR group and 71%
in the OS group. Our study is in agreement with
other reports15,17,21–28 showing comparatively good
results in the early and intermediate follow up of
patients with EVAR, making this technique a viable
alternative to OS in selected cases.
Although EVAR is a safe and effective technique, it
has several limitations. First, it is difficult to prove that
the survival of implanted patients is improved in a
cohort of patients with advanced age and associated
diseases.29 Second, the durability of EVAR has to be
proved. Third, EVAR cannot be applied in all people
suffering from AAA because of anatomic and mor-
phometric limitations.
Clearly EVAR offers advantages in terms of early
recovery. Despite the limitations of comparative
observational studies, like this one, and those already
published.15,17,21–28 there are as yet no results from
prospective and randomized trials. In our study there
are some flaws, such as the retrospective nature of data
collection in the OS group. This could underestimate
the actual incidence of complications. EVAR results
could be disadvantaged by including learning curve
cases and the simultaneous use of different endo-
vascular prostheses, many of them early models not
currently in use. The higher re-intervention rate in
EVAR patients was of borderline significance (pZ
0.0553, Log Rank test), however, the number of events
is too small to reach more accurate estimations. It is
expected that the incidence of endoleaks and related
re-interventions will diminish as new endovascular
prostheses are introduced into clinical practice
In conclusion, in the absence of results of the
ongoing randomized trials, our study has shown
that both techniques are equally effective in prevent-
ing fatal AAA complications at medium term follow
up. EVAR is associated with an associated early
patient recovery. The incidence of re-interventions
after EVAR and the durability of the procedure at
long term follow up remain uncertain. Currently, we
believe that EVAR should be restricted to elderly
patients with serious co-morbidities, with rigorous
clinical follow up.Acknowledgements
This study was supported by the ‘Fellowship grant for
advanced skills in endovascular surgery 2000–2002’ from
The Clı´nic Foundation (Clı´nic Health Corporation). This
work was awarded by Goyanes Prize at the VII International
Congress of the Spanish Language Vascular Surgeons
Society, Miami, USA, 2002, April.References
1 Wilmink ABM, Quick CRG. Br J Surg 1998;85:155–162.
2 Auerback O, Garfinkel L. Atherosclerosis and aneurysm of the
aorta in relation to smoking habits and age. Chest 1980;78:805–
809.
3 Guillum R. Epidemiology of the aortic aneurysms in the United
States. J Clin Epidemiol 1995;48:1289–1298.
4 Ernst CB. Abdominal aortic aneurysm. N Engl J Med 1993;
328:1167–1172.
5 Patel MI, Hardman DT, Fisher CM et al. Current views on the
pathogenesis of the abdominal aortic aneurysms. J Am Coll Surg
1995;181:371–382.
6 Office for National Statistics. Mortality statistics: cause. London
1995.
7 Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal
graft implantation for abdominal aortic aneurysm. Ann Vasc Surg
1991;5:491–499.
8 Harris PL, Buth J, Mialhe C et al. The need for endovascular
abdominal aortic aneurysm stent-graft repair: the EUROSTAR
project. J Endovasc Surg 1997;4:72–77.
9 Rutherford RB, Baker JD, Ernst C et al. Recommended
standards for reports dealing with lower extremity ischemia:
revised version. J Vasc Surg 1997;26:517–538.
10 Owens W, Felts J, Spitznagel E. ASA physical status classifi-
cation: a study of consistency of ratings. Anesthesiology 1978;
49:239–243.
11 Ahn SS, Rutherford RB, Johnston KW et al. Reporting
standards for infrarenal endovascular aortic aneurysm repair.
J Vasc Surg 1997;25:405–410.
12 Chaikof EL, Blankenstein JD, Harris PL et al. Reporting
standards for endovascular aortic aneurysm repair. J Vasc Surg
2002;35:1048–1060.
13 White GH, Yu W, May J et al. Endleak as a complication of
endoluminal grafting of abdominal aortic aneurysms: classifi-
cation, incidence, diagnosis and management. J Endovasc Surg
1997;4:152–168.
14 Buth J, Laheij RJF, on behalf of the EUROSTAR Collaborators.
Early complications and endoleaks after endovascular abdomi-
nal aortic aneurysm repair: report of a multicenter study. J Vasc
Surg 2000;31:134–146.
15 Zarins CK, White RA, Schwarten D et al. AneuRx stent-graft
versus open surgical repair of abdominal aortic aneurysms:
multicenter prospective clinical trial. J Vasc Surg 1999;29:292–308.
16 Chuter TAM, Reilly LM, Faruqi RM et al. Endovascular
aneurysm repair in high-risk patients. J Vasc Surg 2000;31:122–
133.
17 May J, White GH, Yu W et al. Concurrent comparison of
endoluminal versus open repair in the treatment of abdominal
aortic aneurysms: Analysis of 303 patients by life table method.
J Vasc Surg 1998;27:213–221.
18 Dardik A, Lin JW, Gordon TA et al. Results of elective
abdominal aortic aneurysm repair in the 1990s: a population-
based analysis study of 2335 cases. J Vasc Surg 1999;30:985–995.
19 Heller JA, Weinberg A, Arons R et al. Two decades of
abdominal aortic aneurysm repair: have we made any progress?
J Vasc Surg 2000;32:1091–1102.
20 Katz DA, Littenberg B, Cronenwett JL. Management of small
abdominal aortic aneurysms. Early surgery versus watchful
waiting. JAMA 1992;268:2678–2686.
21 Virgilio C, Bui H, Donayre C et al. Endovascular vs. open
abdominal aortic repair. A comparison of cardiac morbidity and
mortality. Arch Surg 1999;134:947–951.
22 White GH, May J, McGahan T et al. Historic control comparison
of outcome for matched groups of patients undergoing endo-
luminal versus open repair of abdominal aortic aneurysms. J Vasc
Surg 1996;23:201–212.
23 Brewster DC, Geller SC, Kaufman JA et al. Initial experience
with endovascular aneurysm repair: comparison of early results
with outcome of conventional open repair. J Vasc Surg 1998;
26:992–998.Eur J Vasc Endovasc Surg Vol 28, October 2004
C. Garcı´a-Madrid et al.37224 Moore WS, Kashyap VS, Vescera CL et al. Abdominal aortic
aneurysm. A 6 year comparison of endovascular versus
transabdominal repair. Ann Surg 1999;3:298–308.
25 Cohnert TU, Oelert F, Wahlers T et al. Matched-pair analysis
of conventional versus endoluminal AAA treatment outcomes
during the initial phase of an aortic endografting program.
J Endovasc Ther 2000;7:94–100.
26 May J, White GH, Waugh R et al. Improved survival after
endoluminal repair with second-generation prostheses com-
pared with open repair in the treatment of abdominal aortic
aneurysms: a 5-year concurrent comparison using life table
method. J Vasc Surg 2001;33:S21–S26.
27 Teufelsbauer H, Prusa AM, Wolf K, Polterauer P,
Nanobashvili J, Prager M et al. Endovascular stent graftingEur J Vasc Endovasc Surg Vol 28, October 2004versus open surgical operation in patients with infrarenal aortic
aneurysms. A propensity score analysis. Circulation 2002;
106:782–787.
28 Hill BB, Wolf YG, Lee A et al. Open versus endovascular AAA
repair in patients who are morphological candidates for
endovascular treatment. J Endovasc Ther 2002;9:255–261.
29 Riambau V, Laheij R, Garcı´a-Madrid C, Sa´nchez G. The
association between co-morbidity and mortality after abdominal
aortic aneurysm endografting in patients ineligible for elective
open surgery. Eur J Vasc Endovasc Surg 2001;22:265–270.
Accepted 15 June 2004
